Valuation: Bolt Biotherapeutics, Inc.

Market Cap 8.11M 7.14M 6.59M 6.16M 11.54M 764M 11.75M 79.14M 30.65M 377M 30.45M 29.79M 1.31B P/E 2026 *
-0.02x
P/E 2027 * -0.02x
Enterprise Value 8.11M 7.14M 6.59M 6.16M 11.54M 764M 11.75M 79.14M 30.65M 377M 30.45M 29.79M 1.31B EV / Sales 2026 *
5.37x
EV / Sales 2027 * 2.32x
Free-Float
96.53%
Yield 2026 *
-
Yield 2027 * -
1 week+5.76%
Current month-19.62%
1 month-17.74%
3 months-6.22%
6 months-20.83%
Current year-22.82%
1 week 3.75
Extreme 3.75
4.4
1 month 3.75
Extreme 3.75
5.7
Current year 3.75
Extreme 3.75
7.2
1 year 3.75
Extreme 3.75
7.2
3 years 3.75
Extreme 3.75
31.2
5 years 3.75
Extreme 3.75
385.7
10 years 3.75
Extreme 3.75
861.4
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 2024-05-14
Chief Executive Officer 54 2024-05-14
Chief Operating Officer 61 2024-05-14
Director TitleAgeSince
Director/Board Member 64 2020-11-30
Director/Board Member 54 2024-05-14
Chairman 55 2024-09-03
Date Insider Type Main position Quantity % Market Cap.
06-09Free

Director

5,000 0.2602%
06-09Free

Chairman

5,000 0.2602%
06-09Free

Director

5,000 0.2602%
Change 5-day change 1-year change 3-year change Capi.($)
0.00%+5.76%-24.78%-83.64% 8.11M
+4.06%+2.05%+61.13%+117.43% 52.88B
+1.58%+19.37%+75.37%+85.18% 50.98B
+0.59%-0.43%-13.65%-15.37% 22.81B
+2.81%+11.63%+1.99%+437.12% 22.43B
+2.03%+10.85%+30.31%-12.32% 17.01B
+0.88%+5.78%+30.82%-33.78% 15.91B
+1.49%+2.95%+22.77%+174.61% 13.29B
+3.02%+18.32%+141.11%+308.04% 13.58B
+1.21%+2.99%+87.60%+121.44% 11.75B
Average +1.74%+4.16%+41.27%+109.87% 22.07B
Weighted average by Cap. +2.21%+4.49%+50.14%+123.21%

Financials

2026 *2027 *
Net sales 1.51M 1.33M 1.23M 1.15M 2.15M 142M 2.19M 14.72M 5.7M 70.15M 5.66M 5.54M 244M 3.5M 3.08M 2.84M 2.66M 4.98M 330M 5.07M 34.16M 13.23M 163M 13.14M 12.86M 566M
Net income -44.52M -39.2M -36.15M -33.81M -63.36M -4.2B -64.54M -434M -168M -2.07B -167M -164M -7.2B -47.5M -41.82M -38.57M -36.08M -67.59M -4.48B -68.86M -464M -180M -2.21B -178M -174M -7.68B
Net Debt - -
Logo Bolt Biotherapeutics, Inc.
Bolt Biotherapeutics, Inc. is a clinical-stage biopharmaceutical company developing immunotherapies for the treatment of cancer. The Company’s pipeline includes BDC-3042, an agonist antibody that activates macrophages by targeting dectin-2, and BDC-4182, a next generation Boltbody Immune-Stimulating Antibody Conjugate (ISAC) clinical candidate targeting claudin 18.2. BDC-3042 is in a Phase I dose escalation trial that includes patients with any of seven different solid tumor types. The Company’s Boltbody ISAC platform technology combines tumor-targeting antibodies with immune-stimulating linker-payloads. It has two additional ISAC programs utilizing its Boltbody ISAC technology platform in preclinical development. One is a Boltbody ISAC targeting carcinoembryonic antigen cell adhesion molecule 5 (CEA). Its final Boltbody ISAC program targets PD-L1. The Company is also developing additional Boltbody ISACs in strategic collaborations with biopharmaceutical companies.
Employees
23
Date Price Change Volume
26-06-25 US$4.220 0.00% 3,501
26-06-24 US$4.220 -1.06% 6,775
26-06-23 US$4.265 +6.36% 28,400
26-06-22 US$4.010 +0.50% 52,862
26-06-18 US$3.990 -5.23% 68,063
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
4
Last Close Price
4.220USD
Average target price
41.00USD
Spread / Average Target
+871.56%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. BOLT Stock